Treatment-experienced people: latest news

Treatment-experienced people resources

Treatment-experienced people features

Treatment-experienced people in your own words

Treatment-experienced people news from aidsmap

More news

Treatment-experienced people news selected from other sources

  • Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

    Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.

    20 March 2019 | Poz
  • South Africa: Shortage of drug puts thousands of Aids patients at risk

    Health authorities have confirmed the shortage of Darunavir, a third-line drug. Third-line drugs are used when patients have few drug options left to treat their condition.

    15 March 2019 | Independent Online
  • Can high-dose dolutegravir be a rescue therapy?

    A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

    12 March 2019 | CATIE
  • Ibalizumab Provides New Option for Patients with Multidrug-Resistant HIV

    A newly published phase 3 study of patients with multidrug-resistant (MDR) HIV shows that ibalizumab can be a safe and effective option for patients with limited other avenues of treatment.

    23 August 2018 | MD Magazine
  • New HIV therapy reduces virus, boosts immunity in drug-resistant patients

    Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

    16 August 2018 | Science Daily
  • Nelson Vergel: Built to Survive

    “There’s wisdom with age, but there’s a lot more wisdom with age and HIV,” says Nelson Vergel. Like many long-term survivors, he initially considered his HIV diagnosis a death sentence. But despite the odds, the Venezuelan immigrant refused to give up.

    29 June 2018 | Poz
  • FDA approves new HIV treatment for patients who have limited treatment options

    Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

    07 March 2018 | FDA
  • CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection

    CytoDyn Inc. (OTC.QB:CYDY) reports the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral therapy (ART) in patients failing their current HIV therapy. The trial data show a statistically significant reduction in HIV-1 RNA viral load of greater than 0.5log with PRO 140 versus placebo. CytoDyn is developing PRO 140, a humanized CCR5 monoclonal antibody, to combat human immunodeficiency virus (HIV) infection and certain immunologic disorders.

    21 February 2018 | CytoDyn press release
  • Antibody-Based HIV Tx Proves Durable

    The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

    10 October 2017 | MedPage Today
  • People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab

    Ibalizumab is a new drug that is effective against drug resistant HIV. It is not approved for sale in the United States, but patients can take advantage of an expanded access program to start treatment right away.

    15 December 2016 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.